Roche Pharma Penzberg
Dr. Klaus Bosslet
In a newly created award, pRED`s Discovery Oncology unit of Roche (RHHBY) in Penzberg, Germany invites European researchers to submit abstracts which describe their scientific work in the field of tumor-selective membrane targets for antibody-based cancer therapy. The award aims to honor and support outstanding research in the academia field and will further strengthen Roche´s interaction with the international research community.
“Roche has a long tradition of successful exchange with many research institutions all over the world,” states Klaus Bosslet, Head of Discovery Oncology Penzberg. “With the new award we emphasize our commitment to intensifying collaboration with academia and continuing support of innovative cancer research.”
The abstracts will be reviewed by a jury consisting of scientific experts from academia and Roche. Qualified applicants include graduate students and postdoctoral fellows from the research labs based in Europe. The authors of the ten best contributions will be invited to the Roche Penzberg campus near Munich, for oral presentation, poster discussion and award ceremony in November 2013. The three winners will be selected at the symposium and receive an award of 4,000 €, 2,000 €, and 1,000 €, respectively.